European Pharmaceutical Review

NOVEMBER 15, 2023

Sandoz] has the only major remaining vertically-integrated production network for penicillins in Europe” Penicillins are the leading category of antibiotics worldwide, Sandoz highlighted. Launch of these new facilities help to ensure sustainable access to quality antibiotics and spearhead development of biosimilars, Sandoz noted.

Medicine 70

Medicine Manufacturing Networking Biopharma 70

Pharmaceutical Technology

MAY 29, 2023

It provides forward-looking analysis of the market including market sizing up to 2026, segmentation by application, potential growth opportunities, and competitive pr Buy the report here.

Pharmaceutical 52

Pharmaceutical Competition Marketing Medicine 52

PM360

SEPTEMBER 21, 2023

The MFPs will be announced publicly in September 2024 and go into effect on January 1, 2026. CMS negotiation may lead to additional savings for beneficiaries and for the Medicare program. Some stakeholders have expressed concern that negotiation could lead to a reduction in drug innovation.

Manufacturing 111

Manufacturing Competition Marketing Physicians 111

World of DTC Marketing

FEBRUARY 22, 2021

billion by 2026. This has abuse potential written all over it and could lead to more dangerous health problems. One of the most common complaints people have is “lack of energy” Consumers have turned to energy drinks which was valued at $53.01 billion in 2018, and is expected to grow at a CAGR of 7.20% to reach $86.01

Pharma 181

Pharma Doctors Side effects Prescription 181

Pharmaceutical Technology

MARCH 10, 2023

At Sandoz, we are determined to continue leading the way in driving access to these critical medicines. Work on the new biologics production plant is expected to commence this year, and complete operations are scheduled to begin in late 2026.

Food and Drug Administration 52

Food and Drug Administration Networking Medicine Food 52

European Pharmaceutical Review

FEBRUARY 8, 2023

It is set to retain its market-leading position as the most lucrative CD19 CAR-T agent in NHL, with annual sales reaching $1.7 Breyanzi is approved for DLBCL, and a label expansion is anticipated for expansions into marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL) in 2026 and 2028, respectively.

Marketing 96

Marketing Sales Physicians Patients 96

European Pharmaceutical Review

MAY 11, 2023

At the same time its 1.875 percent Notes due 2026 will begin trading under ‘RVTY 26.’ Revvity’s Q1 earnings webcast is scheduled on 11 May 2023 at 08:00 ET. Register here. The Company will trade under its new name and the stock ticker symbol ‘RVTY’ at market open on 16 May 2023.

Government 78

Government Prospecting Media Marketing 78

Pharmaceutical Technology

JULY 26, 2022

NPC is a rare inherited disease resulting from the body's inability to conduct intracellular transport of cholesterol and other lipids, leading to the abnormal accumulation of these substances in various bodily tissues, including brain tissue.

Marketing 122

Marketing Transportation Leads Patients 122

pharmaphorum

AUGUST 5, 2022

The structure of the agreement on this drug is a little different, with Innovent developing the drug but Sanofi taking the lead on commercialisation, with the Chinese biotech standing to receive up to €60 million in milestones plus royalties.

Side effects 83

Side effects Marketing Pharma Medicine 83

Pharmaceutical Technology

JULY 28, 2022

Construction work started in Q2 2022 and is expected to be completed in Q1 2026. The project aims to support the growing pipeline position, advanced manufacturing process and Industry-leading investigational RNAi medicines which continue to expand rapidly. Yeosu Dilute Nitric Acid Manufacturing Plant – $135m.

Pharmaceutical 52

Pharmaceutical Manufacturing Medicine Leads 52

pharmaphorum

JULY 26, 2022

That will fund operations until 2026, beyond the readout of phase 3 trials including the BROADWAY study of obicetrapib in adults with heterozygous familial hypercholesterolaemia (HeFH) and/or established atherosclerotic cardiovascular disease (ASCVD) who can’t control LDL cholesterol on statin drugs alone.

Side effects 52

Side effects Safety Pharma Patients 52

Clarivate

OCTOBER 25, 2023

The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

pharmaphorum

SEPTEMBER 8, 2022

The World Health Organization (WHO) issued a report last year that stated that the global burden of GBS is “far higher than previously recognized, linked to over half a million preterm births annually, and leading to nearly 100,000 newborn deaths [and] at least 46,000 stillbirths.”

FDA 52

FDA Leads Marketing 52

pharmaphorum

JANUARY 18, 2023

That pressure can lead to diagnostic errors, with a 2018 study suggesting that there are 40 million errors involving imaging worldwide every year. billion.

Medical 57

Medical Pharma Media Sales 57

pharmaphorum

JANUARY 10, 2023

Research by Treasure Data , a market leading enterprise customer data platform (CDP), shows that HCPs are increasingly turning to digital to research scientific information, new medications, and brands. billion by 2026, according to research by the Business Research Company. Capturing market share. billion in 2021 to $9.23

Marketing 98

Marketing Pharma Healthcare Healthcare 98

Pharmaceutical Technology

MARCH 7, 2023

HRT, or systemic estrogen therapy, is also a leading medication to treat perimenopausal symptoms. With an estimated completion date of May 2026, the study strives to utilise the endocrine biology of perimenopause to explain the behavioural and neurobiological features of depression in perimenopausal women.

Medical 52

Medical Management Leads Pharmaceutical 52

European Pharmaceutical Review

MARCH 9, 2023

There are emerging trends in oncology, with new chemical entities (NCEs) and antibody-drug conjugates (ADC) leading to increased demand for HPAPI manufacturing capabilities. References Global high potency active pharmaceutical ingredient (HPAPI) market report 2022: A $34+ billion market in 2026 – long-term forecast to 2031.

Safety 93

Safety Pharmacology Training Manufacturing 93

pharmaphorum

JANUARY 29, 2023

While global health spending per capita was about US$1,100 in 2018, this is forecast to rise to US$1,700 by 2026, outpacing GDP growth over the same period. Secondly, pressure on healthcare spending is leading to greater consolidation.

Healthcare 87

Healthcare Healthcare Manufacturing Marketing 87

Pharmaceutical Technology

MARCH 22, 2023

Substance use disorders leave people with long-term negative mental and physical health implications and can lead to death. Expected to receive FDA approval by February 2026, the app tracks usage and provides personalised schedules to help reduce use, increase compliance, and reduce pain levels.

Food and Drug Administration 52

Food and Drug Administration Healthcare Healthcare Medical 52

Spotio

NOVEMBER 14, 2023

Some AI tools can emulate human behaviors and interact with prospects and customers in authentic ways, leading to more sales, revenue, and success for users. Like nurturing leads.) If you don’t, your reps will waste time talking to leads who will never convert into paying customers. Why Is It Important to Use AI in Sales?

Sales 52

Sales Prospecting Sales pitches Sales process 52

PM360

APRIL 7, 2023

However, Medicare will only be able to negotiate prices for 10 Part D drugs in 2026, another 15 Part D drugs in 2027, another 15 Part D and Part B drugs in 2028, and another 20 Part D and Part B drugs for 2029 and subsequent years. It’s amazing we still separate the drug costs from overall healthcare costs,” Sontupe says.

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

PM360

APRIL 7, 2023

Dan Renick The IRA presents market access teams with a unique opportunity to make recommendations to CMS regarding the evidence and methodology that will be applied in evaluating drugs for upcoming Medicare negotiations that will lead to price adjustments in 2026. Quality and value measurements commonly used outside of the U.S.

Manufacturing 97

Manufacturing Insurance Government Marketing 97

pharmaphorum

JULY 5, 2022

Prior to this, he founded the industry-leading publication, pharmaphorum, in 2009, which also provides broader content communications and marketing services to enable more effective customer engagement.

Patients 93

Patients Medicine Marketing Recruitment 93

Pharmaceutical Technology

JANUARY 10, 2023

There is a general decline in the major brands across the DPP-4I market, with sitagliptin (Januvia), the former market-leading T2D therapy, undergoing significant market decline with its impending patent expiry in 2027 and the development of sitagliptin generics in the Indian market.

Marketing 52

Marketing Physicians Leads Competition 52

Medico Reach

MARCH 24, 2023

It is estimated that global oncology spending will exceed $300 billion by 2026. Proper research and investment in this field can lead to treating the disease efficiently. The body’s response to cancer treatment improves through treatments such as cellular and gene therapies.

Marketing 52

Marketing Medicine Healthcare Healthcare 52

Medico Reach

MARCH 24, 2023

It is estimated that global oncology spending will exceed $300 billion by 2026. Proper research and investment in this field can lead to treating the disease efficiently. The body’s response to cancer treatment improves through treatments such as cellular and gene therapies.

Marketing 52

Marketing Medicine Healthcare Healthcare 52

Pharmaceutical Technology

AUGUST 12, 2022

In the lead-up to a critical meeting that will influence the approval of a new drug for amyotrophic lateral sclerosis (ALS), the US Food and Drug Administration (FDA) has detailed its plans to advance rare neurodegenerative disease research. The Act authorizes the appropriation of $100,000,000 per fiscal year from 2022 to 2026.

FDA 98

FDA Food and Drug Administration Physicians Side effects 98

Clarify Health

APRIL 26, 2022

health system realize $150 billion in savings by 2026. Chief Innovation Officer at Boston Children’s Hospital and Professor at Harvard Medical School Alissa Hsu Lynch, Global Lead, MedTech Strategy and Solutions at Google Cloud Balaji Ramadoss, Ph.D., Reports indicate that AI can help the U.S. Founder and CEO at Edgilty Inc.

Healthcare 52

Healthcare Healthcare Management Media 52

Clarivate

APRIL 18, 2024

In 2023, Humana’s care delivery component CenterWell launched a senior-centered “ Primary Care Anywhere ” program for in-home primary care in Georgia and Louisiana (where Humana leads the MA sectors) and increased senior membership in value-based home care models nationwide to more than 840,000. Source: News reports and company releases.

Retail 52

Retail Healthcare Healthcare Physicians 52

PM360

SEPTEMBER 21, 2023

GoodRx is the leading platform 2 with the highest unaided awareness and trust across patients, physicians, and pharmacists 3 that Americans—regardless of insurance status—use across many phases of their healthcare journey. United States Specialty Pharmaceuticals Market & Forecast 2020-2026,” BusinessWire, December 8, 2020.

Prescription 52

Prescription Medical Distribution Patients 52

Clarivate

APRIL 24, 2023

Oak Street has 169 locations across 21 states and expects to nearly double its size to 300 centers by 2026. This article was written by Clarivate Lead Healthcare Research and Data Analysts Renée Burnham, Michelle La Vone and Paula Wade. Key acquisitions by U.S. healthcare organizations Company Founded Type No. The post U.S.

Healthcare 89

Healthcare Healthcare Marketing Physicians 89

Clarify Health

MAY 4, 2022

billion by 2026. Learn why Clarify was lauded by Frost & Sullivan for having the leading population health management (PHM) analytics solution and with comprehensive precise SDoH insights. Reports estimate that the healthcare analytics market size is expected to grow to $75.1

Management 52

Management Healthcare Healthcare Training 52

Clarify Health

MAY 4, 2022

billion by 2026. Learn why Clarify was lauded by Frost & Sullivan for having the leading population health management (PHM) analytics solution and with comprehensive precise SDoH insights. Reports estimate that the healthcare analytics market size is expected to grow to $75.1 Get valuable Insights delivered to your inbox.

Management 52

Management Healthcare Healthcare Training 52

Spotio

JUNE 6, 2022

Sales Prospecting Statistics The way companies prospect for leads is changing. HubSpot] 9 in 10 companies use 2+ lead enrichment tools to learn more about prospects. Invest in a toolset that allows you to quickly build profiles and find accurate lead data in your target market. Well, the data suggests otherwise.

Sales 111

Sales Prospecting B2B Sales CRM 111

European Pharmaceutical Review

FEBRUARY 12, 2024

Liam Dunne, MSD Biotech Site Lead, explains that the site operates at the forefront of science and technology with 15,000L-scale, repeatable, robust manufacturing processes to produce highly sensitive monoclonal antibodies (mAbs). How does it do this? Since 2021, Liam Dunne is the site head of MSD Biotech in Dublin.

Manufacturing 92

Manufacturing Medicine Leads Media 92

Spotio

APRIL 21, 2023

Recent research shows that the hardware as a service market (HaaS) should reach $300+ billion in 2026. The tips, tricks, and best practices below will help your team excel at both, leading to more revenue for your company. Simple: tell your reps to contact X amount of leads a day. Do you sell POS systems? Who are they?

Sales 52

Sales Prospecting Leads Sales pitches 52

Pharmaceutical Technology

APRIL 28, 2023

Key among them has been the extension of Syngene’s research collaboration with leading biotech company Amgen Inc. until 2026. Another notable contract that the company recently signed was with the leading Animal Health company, Zoetis. For more details, visit www.syngeneintl.com HQ ADDRESS: Syngene International Ltd.

Manufacturing 52

Manufacturing Government Pharmaceutical Leads 52